Suggestions
Ravi Bhatia
Sr. Scientific Director at Johnson & Johnson
Ravi Bhatia is a Senior Scientific Director at Johnson & Johnson Innovative Medicine with extensive experience in biopharmaceutical research and development.1 Here are some key details about his professional background:
Current Role
Ravi Bhatia currently serves as the Sr. Scientific Director at Johnson & Johnson Innovative Medicine, a position he has held since September 2023.1
Career History
Johnson & Johnson:
- Scientific Director (April 2014 - October 2023)
- Associate Director (January 2010 - February 2013)
Centocor:
- Principal Engineer (November 2007 - August 2010)
- Sr. Engineer (2004 - 2007)
Previous Experience:
- Engineer at Human Genome Sciences (2000 - 2004)
- Engineer at Bristol-Myers Squibb (September 1997 - December 2000)
Expertise and Achievements
Ravi is known for his expertise in:
- Cell therapy and viral vaccine product development
- Process development and scale-up for biopharmaceutical manufacturing
- Implementation of single-use technologies
Some of his notable achievements include:
- Leading a team to develop and scale-up cell therapy and viral vaccine-based products.1
- Developing and implementing the industry's first large-scale single-use bioreactor (1000L) and a single-use fluidized bed centrifuge technology for biopharmaceutical manufacturing.1
- Leading a team to develop an upstream commercial process for Benlysta®, an FDA-approved antibody for the treatment of SLE.1
Education
Ravi Bhatia received his BSc and MSc in Chemical Engineering from the University of Pittsburgh, graduating in 1995.1
Additional Information
Ravi has delivered numerous invited presentations on the development and implementation of single-use technologies for biopharmaceutical manufacturing. He has also authored publications on cell physiology and single-use technologies.1
